Reduced IL-1β levels and the lack of clinical response to treatment with IL-1 blockers argue against NLRP3 inflammasome hyperactivation being the main mechanism mediating the APLAID pathogenesis. Here, NLRP3 is linked to autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation.